In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BiomX (PHGE), with a price target of $20.00. The company’s shares closed last Monday at $6.27.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 36.9% and a 60.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
BiomX has an analyst consensus of Strong Buy, with a price target consensus of $22.50.
See today’s analyst top recommended stocks >>
Based on BiomX’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $8.4 million. In comparison, last year the company had a GAAP net loss of $5.9 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
Read More on PHGE:
